NOVEL ANTITHROMBOTIC ANTIBODY

The present invention provides a novel antithrombotic antibody, the antibody uses FIXa as a target and has unique properties, and specifically targets the binding site of coagulation factor FIXa and FVIIIa, reduces the formation of a FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and there...

Full description

Saved in:
Bibliographic Details
Main Authors LIU, JUNLING, SUN, TIANYAO, FAN, XUEMEI
Format Patent
LanguageEnglish
French
Published 15.12.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a novel antithrombotic antibody, the antibody uses FIXa as a target and has unique properties, and specifically targets the binding site of coagulation factor FIXa and FVIIIa, reduces the formation of a FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and thereby exerts an antithrombotic effect. The antibody of the present invention has suitable antithrombotic properties, and has a large effective therapeutic concentration window, but does not increase the risk of bleeding; in addition, the antibody can meet the needs for suitable antithrombotic performance in clinical application and for effective avoidance of problems regarding bleeding caused by excessive effects. The present invention also discloses a method for screening drugs by using an FIXa-FVIIIa binding site as a target. La présente invention concerne un nouvel anticorps antithrombotique, l'anticorps utilise FIXa en tant que cible et possède des propriétés uniques, et cible de manière spécifique le site de liaison du facteur de coagulation FIXa et FVIIIa, réduit la formation d'un complexe FVIIIa-FIXa, bloque la conversion du FX en FXa, et exerce ainsi un effet antithrombotique. L'anticorps selon la présente invention a des propriétés antithrombotiques appropriées, et a un grand intervalle de concentration thérapeutique efficace, mais n'augmente pas le risque de saignement; de plus, l'anticorps peut satisfaire aux besoins pour une performance antithrombotique appropriée dans une application clinique et pour éviter efficacement des problèmes concernant le saignement provoqués par des effets excessifs. La présente invention concerne également un procédé de criblage de médicaments à l'aide d'un site de liaison FIXa-FVIIIa en tant que cible.
Bibliography:Application Number: CA20223222103